Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Oculogenex
company
About
Oculogenex is a biopharmaceutical company that specializes in gene therapy for the treatment of retinal disorders.
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $1M
- Industries
- Biopharma,Biotechnology,Pharmaceutical
- Founded date
- Jan 1, 2020
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Oculogenex is a biopharmaceutical company that specializes in gene therapy for the treatment of retinal disorders. The company was founded in 2020 and is headquartered in La Habra, California.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$1.25M
Oculogenex has raised a total of
$1.25M
in funding over 2 rounds. Their latest funding was raised on
May 2, 2022 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 2, 2022 | Grant | $1M | 1 |
National Science Foundation
|
— | Detail |
| Apr 21, 2021 | Grant | $256K | 1 |
National Science Foundation
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
1
Oculogenex is funded by 1 investors.
National Science Foundation
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Science Foundation
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
